A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis

Roberto Furlan; Asli Kurne; Alessandra Bergami; Elena Brambilla; Raffaella Maucci; Laura Gasparini; Erica Butti; Giancarlo Comi; Ennio Ongini; Gianvito Martino

doi:10.1016/j.jneuroim.2004.01.004

A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis

Roberto Furlan, Asli Kurne, Alessandra Bergami, Elena Brambilla, Raffaella Maucci, Laura Gasparini, Erica Butti, Giancarlo Comi, Ennio Ongini, Gianvito Martino

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Nitric oxide (NO)-releasing non-steroidal anti-inflammatory drugs (NSAIDs) have been reported to have a safer profile and additional anti-inflammatory and immuno-modulatory properties compared to parent compounds. Preventive treatment of experimental autoimmune encephalomyelitis (EAE)-induced in C57BL/6 mice by immunization with myelin oligodendrocyte glycoprotein (MOG) peptide 35-55-with the NO-releasing derivative of flurbiprofen HCT1026 delayed disease onset and significantly decreased disease severity. HCT1026 treatment was associated to (i) decreased mRNA levels of pro-inflammatory cytokines, caspase-1, and iNOS in blood cells; (ii) decreased ability of encephalitogenic T cells to proliferate; (iii) reduced number of central nervous system (CNS)-infiltrating T cells; (iv) decreased axonal loss and demyelination; (v) increased CD4⁺ CD69 ^- CD25⁺ regulatory T cells in the spleen.

Original language	English
Pages (from-to)	10-19
Number of pages	10
Journal	Journal of Neuroimmunology
Volume	150
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jneuroim.2004.01.004
Publication status	Published - May 2004

Keywords

Caspase-1
EAE
IFN-γ
IL-10k/o
Nitric oxide
NSAID

ASJC Scopus subject areas

Immunology
Clinical Neurology
Immunology and Allergy
Neurology

Access to Document

10.1016/j.jneuroim.2004.01.004

Fingerprint Dive into the research topics of 'A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis'. Together they form a unique fingerprint.

Cite this

A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis. / Furlan, Roberto; Kurne, Asli; Bergami, Alessandra; Brambilla, Elena; Maucci, Raffaella; Gasparini, Laura; Butti, Erica ; Comi, Giancarlo; Ongini, Ennio; Martino, Gianvito.

In: Journal of Neuroimmunology, Vol. 150, No. 1-2, 05.2004, p. 10-19.

Research output: Contribution to journal › Article › peer-review

@article{bb6f6e02fae941a2adc065b8967f7399,

title = "A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis",

abstract = "Nitric oxide (NO)-releasing non-steroidal anti-inflammatory drugs (NSAIDs) have been reported to have a safer profile and additional anti-inflammatory and immuno-modulatory properties compared to parent compounds. Preventive treatment of experimental autoimmune encephalomyelitis (EAE)-induced in C57BL/6 mice by immunization with myelin oligodendrocyte glycoprotein (MOG) peptide 35-55-with the NO-releasing derivative of flurbiprofen HCT1026 delayed disease onset and significantly decreased disease severity. HCT1026 treatment was associated to (i) decreased mRNA levels of pro-inflammatory cytokines, caspase-1, and iNOS in blood cells; (ii) decreased ability of encephalitogenic T cells to proliferate; (iii) reduced number of central nervous system (CNS)-infiltrating T cells; (iv) decreased axonal loss and demyelination; (v) increased CD4+ CD69 - CD25+ regulatory T cells in the spleen.",

keywords = "Caspase-1, EAE, IFN-γ, IL-10k/o, Nitric oxide, NSAID",

author = "Roberto Furlan and Asli Kurne and Alessandra Bergami and Elena Brambilla and Raffaella Maucci and Laura Gasparini and Erica Butti and Giancarlo Comi and Ennio Ongini and Gianvito Martino",

year = "2004",

month = may,

doi = "10.1016/j.jneuroim.2004.01.004",

language = "English",

volume = "150",

pages = "10--19",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier Science B.V.",

number = "1-2",

}

TY - JOUR

T1 - A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis

AU - Furlan, Roberto

AU - Kurne, Asli

AU - Bergami, Alessandra

AU - Brambilla, Elena

AU - Maucci, Raffaella

AU - Gasparini, Laura

AU - Butti, Erica

AU - Comi, Giancarlo

AU - Ongini, Ennio

AU - Martino, Gianvito

PY - 2004/5

Y1 - 2004/5

N2 - Nitric oxide (NO)-releasing non-steroidal anti-inflammatory drugs (NSAIDs) have been reported to have a safer profile and additional anti-inflammatory and immuno-modulatory properties compared to parent compounds. Preventive treatment of experimental autoimmune encephalomyelitis (EAE)-induced in C57BL/6 mice by immunization with myelin oligodendrocyte glycoprotein (MOG) peptide 35-55-with the NO-releasing derivative of flurbiprofen HCT1026 delayed disease onset and significantly decreased disease severity. HCT1026 treatment was associated to (i) decreased mRNA levels of pro-inflammatory cytokines, caspase-1, and iNOS in blood cells; (ii) decreased ability of encephalitogenic T cells to proliferate; (iii) reduced number of central nervous system (CNS)-infiltrating T cells; (iv) decreased axonal loss and demyelination; (v) increased CD4+ CD69 - CD25+ regulatory T cells in the spleen.

AB - Nitric oxide (NO)-releasing non-steroidal anti-inflammatory drugs (NSAIDs) have been reported to have a safer profile and additional anti-inflammatory and immuno-modulatory properties compared to parent compounds. Preventive treatment of experimental autoimmune encephalomyelitis (EAE)-induced in C57BL/6 mice by immunization with myelin oligodendrocyte glycoprotein (MOG) peptide 35-55-with the NO-releasing derivative of flurbiprofen HCT1026 delayed disease onset and significantly decreased disease severity. HCT1026 treatment was associated to (i) decreased mRNA levels of pro-inflammatory cytokines, caspase-1, and iNOS in blood cells; (ii) decreased ability of encephalitogenic T cells to proliferate; (iii) reduced number of central nervous system (CNS)-infiltrating T cells; (iv) decreased axonal loss and demyelination; (v) increased CD4+ CD69 - CD25+ regulatory T cells in the spleen.

KW - Caspase-1

KW - EAE

KW - IFN-γ

KW - IL-10k/o

KW - Nitric oxide

KW - NSAID

UR - http://www.scopus.com/inward/record.url?scp=11144353904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144353904&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2004.01.004

DO - 10.1016/j.jneuroim.2004.01.004

M3 - Article

C2 - 15081244

AN - SCOPUS:11144353904

VL - 150

SP - 10

EP - 19

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -